天然产物研究与开发 ›› 2023, Vol. 35 ›› Issue (1): 139-150.doi: 10.16333/j.1001-6880.2023.1.015

• 数据研究 • 上一篇    下一篇

基于数据挖掘与网络药理学的慢性心力衰竭中医证型、用药规律及相关药理分析

魏佳明1,4,刘承鑫1,李   雅2,郭志华3,4*   

  1. 学院;4湖南中医药大学慢病中医智能诊断与治未病湖南省普通高等学校重点实验室,长沙 410208
  • 出版日期:2023-01-28 发布日期:2023-02-20
  • 基金资助:
    国家自然科学基金(82174343);湖南省研究生科研创新项目(CX20210693);湖南中医药大学湖南省“国内一流建设学科”中医学开放基金(2021ZYX14);湖南中医药大学大学生创新创业训练计划(S202010541013)

Traditional Chinese medicine syndrome,medication rules and related pharmacological analysis of chronic heart failure based on data mining and network pharmacology

WEI Jia-ming1,4,LIU Cheng-xin1,LI Ya2,GUO Zhi-hua3,4*   

  1. 1湖南中医药大学第一中医临床学院;2湖南中医药大学药学院;3湖南中医药大学中医学院;4湖南中医药大学慢病中医智能诊断与治未病湖南省普通高等学校重点实验室,长沙 410208
  • Online:2023-01-28 Published:2023-02-20

摘要:

基于数据挖掘及网络药理学技术,研究慢性心力衰竭(chronic heart failure,CHF)中医证型及用药规律特点,并对出现频率最高的药组进行相关药理分析。通过检索中国知网、万方及维普数据库自建库以来至2022年2月发表在核心期刊的关于中医药治疗慢性心衰的文献,对其中有效处方的中医证型及用药规律进行研究,并分析最高频药组治疗CHF的成分、靶点、作用通路等。共筛选出方剂214首,中药148味,其中黄芪、丹参、茯苓、甘草、附子、葶苈子等使用频次最高;中医证型主要为阳虚水泛证及气虚血瘀证;药物性味以温、平、微寒及甘、辛、苦为主,主要归肺、脾、心经,功效以补虚、活血化瘀、利水渗湿为主;关联规则分析获得11对药组,其中黄芪-丹参出现频次最高;聚类分析得到4个聚类方;网络药理学分析得到高频药组黄芪-丹参治疗CHF的主要活性成分5种,核心靶点10个,涉及的主要信号通路6条。通过数据挖掘发现慢性心力衰竭的中医证型以阳虚水泛证及气虚血瘀证为主,中医药治疗以补虚药、活血化瘀药、利水渗湿药居多,常与药性温、平、微寒,药味甘、辛、苦,归肺、脾、心经的药物配伍使用。其中高频药组黄芪-丹参可能通过VEGF信号通路、脂质与动脉粥样硬化信号通路、松弛素信号通路、HIF-1信号通路、ErbB信号通路、FoxO信号通路等发挥抗心衰的作用机制,为进一步中医治疗CHF的临床用药及机制研究提供了参考。

关键词: 慢性心力衰竭, 数据挖掘, 网络药理, 中医证型, 用药规律, 作用机制

Abstract:

Based on data mining and network pharmacology technology,this study explored the Traditional Chinese Medicine (TCM) syndrome and medication rules in the treatment of chronic heart failure (CHF),and analyzed the drug group with the highest frequency of occurrence through network pharmacology.The literatures on the treatment of CHF with Chinese Medicine published in the core journals from the establishment of the database to February 2022 were searched,then the TCM syndrome and medication rules of effective prescriptions were analyzed;meanwhile,the components,targets and signaling pathways of the highest frequency drug group in treating CHF were analyzed.A total of 214 related prescriptions and 148 Chinese medicines were selected,among which Astragali Radix,Salviae Miltiorrhizae Radix et Rhizoma,Poria,Glycyrrhizae Radix et Rhizoma,Aconiti Lateralis Radix Praeparata,Descurainiae Semen were most frequently used;the main TCM syndrome was Yang deficiency with water flooding syndrome and Qi deficiency with blood stasis syndrome;the medicinal flavor was mainly warm,calm,slightly cold,and sweet,pungent,bitter,which mainly belonged to the lung,spleen and heart meridians;the drugs efficacy was mainly classified as restorative Chinese herbal medicines (CHMs),CHMs for invigorating circulation and removing blood stasis,CHMs for promoting water and dampness.Through association rule analysis,11 pairs of drug groups were obtained,in which Astragali Radix-Salviae Miltiorrhizae Radix et Rhizoma showed the highest frequency;and four cluster prescriptions were obtained by cluster analysis.The results of network pharmacological analysis showed that there were five main active compounds,ten core targets,six signaling pathway of Astragali Radix-Salviae Miltiorrhizae Radix et Rhizoma to treat CHF.Through data mining,we find that the TCM syndrome of CHF are mainly Yang deficiency with water flooding syndrome and Qi deficiency with blood stasis syndrome,and the commonly used medicines in TCM treatment were restorative CHMs,CHMs for invigorating circulation and removing blood stasis,CHMs for promoting water and dampness,which were often used in combination with warm,calm,slightly cold,and sweet,pungent,bitter,and belonging to the lung,spleen and heart meridians.VEGF signaling pathway,lipid and atherosclerosis,relaxin signaling pathway,HIF-1 signaling pathway,ErbB signaling pathway,FoxO signaling pathway were the main ways of Astragali Radix-Salviae Miltiorrhizae Radix et Rhizoma to treat CHF.It provides a reference for further clinical medication and mechanism research of TCM in the treatment of CHF.

Key words: chronic heart failure, data mining, network pharmacology, TCM syndrome, medication rules, mechanism research

中图分类号:  R256.2